Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight
  • Published:

Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy

Leukemia volume 19, pages 1517–1524 (2005)Cite this article

Abstract

An antisense strategy by targeting both bcr3/abl2 and VEGF was designed to suppress the growth of Philadephia1 leukemia cells in vitro and in vivo in mice. In vitro, although bcr3/abl2 or VEGF antisense oligodeoxyribonucleotides (AS-ODNs) alone was able to inhibit the proliferation of K562 cells, the combination of bcr3/abl2 and VEGF AS-ODNs produced an additive inhibitory effect on the growth of K562 cells and significantly enhanced the sensibility of K562 cells to apoptosis-inducing stimuli including STI571. In vivo, the nude mice xenografted with K562 cells received intratumoral injections of bcr3/abl2 and VEGF AS-ODNs showed a significant reduction in leukemia tumor size and microvessel density and an increase of apoptosis in the tumors when compared to the mice that received an individual agent. These results demonstrate that targeting both bcr3/abl2 and VEGF can result in an additive tumor-suppressive action and may represent an excellent strategy to augment the efficacy of chemotherapy in CML.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 3
Figure 1
Figure 2

References

  1. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ . Inhibition of apoptosis by BCR/ABL in chronic myelogenous leukemia. Blood 1994; 83: 2038–2044.

    CAS  PubMed  Google Scholar 

  2. Sirard C, Laneuville P, Dick JE . Expression of BCR/ABL abrogates factor-dependent growth of human hematopoietic M07e cells by an autocrine mechanism. Blood 1994; 83: 1575–1585.

    CAS  PubMed  Google Scholar 

  3. Verfaillie CM, McCarthy JB, McGlave PB . Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. J Clin Invest 1992; 90: 1232–1249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P et al. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion and homing. Blood 1998; 91: 406–418.

    CAS  PubMed  Google Scholar 

  5. Yang RC, Han ZC . Angiogenesis in hematological malignancies and its clinical implications. Int J Hematol 2002; 75: 246–256.

    Article  PubMed  Google Scholar 

  6. Liu P, Wang Y, Li YH, Yang C, Zhou YL, Li B et al. Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leukemia Res 2003; 27: 701–708.

    Article  CAS  Google Scholar 

  7. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al. VEGF regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954–958.

    Article  CAS  PubMed  Google Scholar 

  8. Janowska-Wieczorek A, Majka M, Marquez-Curtis L, Wertheim JA, Turner AR, Ratajczak MZ . Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 2002; 16: 1160–1166.

    Article  CAS  PubMed  Google Scholar 

  9. Druker BJ, Lydon NB . Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. He R, Liu B, Yang C, Yang RC, Tobelem G, Han ZC . Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence. Cancer Gene Ther 2003; 10: 879–886.

    Article  CAS  PubMed  Google Scholar 

  11. Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E et al. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res 2002; 1: 89–95.

    CAS  PubMed  Google Scholar 

  12. Skorski T, Szczylick C, Malaguarnera L, Calabretta B . Gene targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem Cytobiol 1991; 29: 85–89.

    CAS  PubMed  Google Scholar 

  13. Li XM, Tang ZY, Zhou G, Lui YK, Ye SL . Significant of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 1998; 17: 1–3.

    Google Scholar 

  14. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B . Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood 1996; 88: 1005–1012.

    CAS  PubMed  Google Scholar 

  15. Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M . Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 2001; 97: 2846–2853.

    Article  CAS  PubMed  Google Scholar 

  16. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M et al. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but non-antisense mechanism. Blood 1995; 86: 3891–3896.

    CAS  PubMed  Google Scholar 

  17. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539.

    Article  CAS  PubMed  Google Scholar 

  18. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.

    Article  CAS  PubMed  Google Scholar 

  19. Weisberg E, Griffin JD . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498–3505.

    CAS  PubMed  Google Scholar 

  20. Keeshan K, Mills KI, Cotter TG, McKenna SL . Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001; 15: 1823–1833.

    Article  CAS  PubMed  Google Scholar 

  21. Nimmanapalli R, O'Bryan E, Bhalla K . Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61: 1799–1804.

    CAS  PubMed  Google Scholar 

  22. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999–2007.

    Article  CAS  PubMed  Google Scholar 

  23. Porosnicu M, Nimmanapalli R, Nguyen D, Worthington E, Perkins C, Bhalla KN . Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia 2001; 15: 772–778.

    Article  CAS  PubMed  Google Scholar 

  24. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C et al. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 2001; 7: 350–357.

    CAS  PubMed  Google Scholar 

  25. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91: 163–168.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the grants of National Development Plan of High Technology 863 (2001AA215311, 2002AA223354) and 973 (001CB5101) projects from the Ministry of Science & Technology of China to ZC Han.

Author information

Authors and Affiliations

  1. State Key Laboratory of Experimental Hematology, National Research Center for Stem Cell Engineering & Technology, Tianjin, China

    X L Cong, B Li & Z C Han

  2. Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union of Medical College, Tianjin, China

    R C Yang, S Z Feng & Z C Han

  3. Shanghai Institute of Hematology, Shanghai Second Medical University, Shanghai, China

    S J Chen

Authors
  1. X L Cong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R C Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Z Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S J Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z C Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Z C Han.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cong, X., Li, B., Yang, R. et al. Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy. Leukemia 19, 1517–1524 (2005). https://doi.org/10.1038/sj.leu.2403851

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403851

Keywords

This article is cited by

Search

Advanced search

Quick links